clinical
-
COVID-19
Hospitals paying $24 billion more for labor during the COVID-19 pandemic
Clinical labor costs are up by an average of 8% per patient day, translating to $17 million in additional annual…
Read More » -
Recon
Clinical Pilot Study Confirms the Accuracy and Effectiveness of Pixee Medical’s Knee+ Solution Using Vuzix M400 Smart Glasses for Total Knee Arthroplasty
– Vuzix receives follow-on M400 Smart Glasses order from Pixee Medical ROCHESTER, N.Y., Sept. 17, 2021 /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the…
Read More » -
Spine
Curiteva Adds Steve Cichy as Strategic Advisor and Erik Erbe, PhD, as Vice President of Clinical and Research
Curiteva adds two additional industry experts to help strategically lead the company and the development of its novel technology for…
Read More » -
Extremities
Should an Orthopaedic Rotation be Mandated in Medical School?
Elizabeth Hofheinz, M.P.H., M.Ed. A team of forward-thinking researchers from The Johns Hopkins University set out to understand how “the…
Read More » -
Biologics
Ortho Regenerative Technologies Announces the Nomination of its New Vice-president Clinical and Medical Affairs
MONTREAL, Oct. 19, 2020 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (“Ortho RTI” or the “Company“), an emerging orthobiologics company focused on…
Read More » -
Biologics
BBS-Bioactive Bone Substitutes Plc: We are pleased to announce that the clinical result of ARTEBONE® is positive yielding an outcome similar to patient’s own bone graft
19.2.2020 The clinical investigation run by BBS-Bioactive Bone Substitutes Oyj in clinical centers in Finland and Poland has been finalized…
Read More » -
Financial
Embody, Inc. Extends DARPA Funding to $14.35 Million
NORFOLK, Va., Jan. 14, 2020 /PRNewswire/ —Embody, Inc., a privately-held medical device company focused on soft tissue repair, announced today they have…
Read More » -
Spine
First Clinical Publication in Japan for the SpineGuard DSG® Technology
December 16, 2019 PARIS & BOULDER, Colo.–(BUSINESS WIRE)–Regulatory News: SpineGuard (Paris:ALSGD) (FR0011464452 – ALSGD), an innovative company that deploys its DSG®…
Read More » -
Biologics
Anika Appoints Mira Leiwant as Vice President of Regulatory Affairs, Quality, and Clinical Affairs
October 14, 2019 BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated company, focused on developing regenerative therapies leveraging its…
Read More » -
Biologics
Early data demonstrate motor function improvement for spinal cord stem cell treatment
26th January 2017 A new therapy to treat spinal cord injuries in people who have lost all motor and sensory…
Read More » -
Extremities
Bioness StimRouter™ Neuromodulation System Clinical Data Presented At The 2017 North American Neuromodulation Society’s Annual Meeting
VALENCIA, Calif., Jan. 20, 2017 /PRNewswire/ — Bioness, Inc., the leading provider of state-of-the-art, clinically supported rehabilitation and pain management medical devices,…
Read More » -
Sports Medicine
Histogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine
WALTHAM, Mass., Jan. 11, 2017 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (HSGX), a regenerative medicine company focused on developing and…
Read More » -
Biologics
InVivo Therapeutics Announces INSPIRE’S 29th Clinical Site: Rhode Island Hospital
January 10, 2017 CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that Rhode Island Hospital in Providence, RI has been…
Read More » -
Biologics
SpinalCyte, LLC Receives Institutional Review Board Approval for Phase I Clinical Trial
December 13, 2016 HOUSTON–(BUSINESS WIRE)–SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus…
Read More » -
Spine
Implanet Presents JAZZ Band Clinical Results in Hypokyphotic Idiopathic Scoliosis Patients
December 06, 2016 BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News: IMPLANET (Paris:IMPL) (OTCQX:IMPZY) (Euronext: IMPL, FR0010458729, PEA-PME eligible; OTCQX: IMPZY), a medical…
Read More »